相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Simplified molecular classification of lung adenocarcinomas based on EGFR, KRAS, and TP53 mutations
Roberto Ruiz-Cordero et al.
BMC CANCER (2020)
The prognostic impact of TP53 comutation in EGFR mutant lung cancer patients: a systematic review and meta-analysis
Rui Zhang et al.
POSTGRADUATE MEDICINE (2019)
Concurrent Driver Gene Mutations as Negative Predictive Factors in Epidermal Growth Factor Receptor-Positive Non-Small Cell Lung Cancer
Minjiang Chen et al.
EBIOMEDICINE (2019)
K-ras Mutation Subtypes in NSCLC and Associated Co-occuring Mutations in Other Oncogenic Pathways
Matthias Scheffler et al.
JOURNAL OF THORACIC ONCOLOGY (2019)
Concurrent TP53 mutations predict poor outcomes of EGFR-TKI treatments in Chinese patients with advanced NSCLC
Helei Hou et al.
CANCER MANAGEMENT AND RESEARCH (2019)
Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer
Alessandro Leonetti et al.
BRITISH JOURNAL OF CANCER (2019)
Tumor clonality and resistance mechanisms in EGFR mutation-positive non-small-cell lung cancer: implications for therapeutic sequencing
Shinji Kohsaka et al.
FUTURE ONCOLOGY (2019)
EGFR-Mutant Adenocarcinomas That Transform to Small-Cell Lung Cancer and Other Neuroendocrine Carcinomas: Clinical Outcomes
Nicolas Marcoux et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Concurrent Alterations in EGFR-Mutant Lung Cancers Associated with Resistance to EGFR Kinase Inhibitors and Characterization of MTOR as a Mediator of Resistance
Helena A. Yu et al.
CLINICAL CANCER RESEARCH (2018)
Elucidating the genomic architecture of Asian EGFR-mutant lung adenocarcinoma through multi-region exome sequencing
Rahul Nahar et al.
NATURE COMMUNICATIONS (2018)
Cumulative smoking dose affects the clinical outcomes of EGFR-mutated lung adenocarcinoma patients treated with EGFR-TKIs: a retrospective study
In Ae Kim et al.
BMC CANCER (2018)
Mutations in TP53, PIK3CA, PTEN and other genes in EGFR mutated lung cancers: Correlation with clinical outcomes
Paul A. VanderLaan et al.
LUNG CANCER (2017)
Evolution and clinical impact of co-occurring genetic alterations in advanced-stage EGFR-mutant lung cancers
Collin M. Blakely et al.
NATURE GENETICS (2017)
Reduced expression levels of PTEN are associated with decreased sensitivity of HCC827 cells to icotinib
Yang Zhai et al.
ONCOLOGY LETTERS (2017)
Prospective Comprehensive Molecular Characterization of Lung Adenocarcinomas for Efficient Patient Matching to Approved and Emerging Therapies
Emmet J. Jordan et al.
CANCER DISCOVERY (2017)
EGFR mutation, smoking, and gender in advanced lung adenocarcinoma
Chien-Hua Tseng et al.
ONCOTARGET (2017)
ATM mutations and E-cadherin expression define sensitivity to EGFR-targeted therapy in colorectal cancer
Anna-Lena Geissler et al.
ONCOTARGET (2017)
P53 non-disruptive mutation is a negative predictive factor in EGFR M plus NSCLC treated with TKI
F. Griesinger et al.
ANNALS OF ONCOLOGY (2016)
Enhanced gefitinib-induced repression of the epidermal growth factor receptor pathway by ataxia telangiectasia-mutated kinase inhibition in non-small-cell lung cancer cells
Keizo Misumi et al.
CANCER SCIENCE (2016)
Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT)
Fabrice Barlesi et al.
LANCET (2016)
Impact of Smoking Status on EGFR-TKI Efficacy for Advanced Non-Small-Cell Lung Cancer in EGFR Mutants: A Meta-analysis
Yaxiong Zhang et al.
CLINICAL LUNG CANCER (2015)
Mechanisms of Acquired Resistance to AZD9291 A Mutation-Selective, Irreversible EGFR Inhibitor
Tae Min Kim et al.
JOURNAL OF THORACIC ONCOLOGY (2015)
Comprehensive molecular profiling of lung adenocarcinoma
Eric A. Collisson et al.
NATURE (2014)
Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial
Tetsuya Mitsudomi et al.
LANCET ONCOLOGY (2010)
Gefitinib or Chemotherapy for Non-Small-Cell Lung Cancer with Mutated EGFR.
Makoto Maemondo et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
PTEN Loss Contributes to Erlotinib Resistance in EGFR-Mutant Lung Cancer by Activation of Akt and EGFR
Martin L. Sos et al.
CANCER RESEARCH (2009)
Gefitinib or Carboplatin-Paclitaxel in Pulmonary Adenocarcinoma.
Tony S. Mok et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Loss of PTEN/MMAC1/TEP in EGF receptor-expressing tumor cells counteracts the antitumor action of EGFR tyrosine kinase inhibitors
R Bianco et al.
ONCOGENE (2003)
分享论文
